Literature DB >> 18226671

Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo.

Freedolph D Anderson1, Robert Feldman, Kathleen Z Reape.   

Abstract

BACKGROUND: The study was conducted to evaluate the effects of a 91-day extended-regimen oral contraceptive (OC) containing levonorgestrel (LNG) with low-dose ethinyl estradiol (EE) in place of placebo on endometrial histology. STUDY
DESIGN: Endometrial biopsies were obtained prior to initiation and posttreatment, between cycle Days 60 and 84 (during combination EE/LNG tablets), between cycle Days 85 and 91 (during low-dose EE tablets) or after completion of therapy.
RESULTS: Paired endometrial biopsy samples obtained before and after treatment were available for 63 subjects. Biopsy results demonstrated that this OC regimen did not promote unexpected changes in the endometrium, either during the course of active treatment with EE/LNG or during the 7-day low-dose EE interval. Endometrial hyperplasia or malignancy was not observed in any endometrial biopsy sample.
CONCLUSION: Use of a 91-day extended-regimen OC with low-dose EE in place of placebo was not associated with any untoward effects on the endometrium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226671     DOI: 10.1016/j.contraception.2007.11.006

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

Review 1.  Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive.

Authors:  Celeste B Burness
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

2.  Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Ann Epidemiol       Date:  2009-01       Impact factor: 3.797

3.  Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest.

Authors:  Johannes Bitzer; Susanne Parke; Thomas Roemer; Marco Serrani
Journal:  Int J Womens Health       Date:  2011-04-18

4.  Long-term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study.

Authors:  Christine Klipping; Ingrid Duijkers; Michel P Fortier; Joachim Marr; Dietmar Trummer; Jörg Elliesen
Journal:  J Fam Plann Reprod Health Care       Date:  2012-04

5.  Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval.

Authors:  Rossella E Nappi; Paloma Lobo Abascal; Jennifer Hsieh; Marie-Christine Micheletti
Journal:  Int J Womens Health       Date:  2017-10-05

Review 6.  Menstrual suppression: current perspectives.

Authors:  Paula Adams Hillard
Journal:  Int J Womens Health       Date:  2014-06-23

Review 7.  Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians.

Authors:  Rossella E Nappi; Andrew M Kaunitz; Johannes Bitzer
Journal:  Eur J Contracept Reprod Health Care       Date:  2015-11-17       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.